Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
285.31
+1.91 (0.67%)
At close: May 16, 2025, 4:00 PM
280.02
-5.29 (-1.85%)
After-hours: May 16, 2025, 7:55 PM EDT
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 24 professional analysts, the 12-month price target for Alnylam Pharmaceuticals stock ranges from a low of $220 to a high of $500. The average analyst price target of $324.54 forecasts a 13.75% increase in the stock price over the next year.
Price Target: $324.54 (+13.75%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 11 | 11 | 12 |
| Buy | 7 | 8 | 8 | 9 | 9 | 9 |
| Hold | 5 | 5 | 4 | 3 | 3 | 3 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 24 | 23 | 24 | 24 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $331 → $349 | Strong Buy | Maintains | $331 → $349 | +22.32% | May 2, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $300 → $325 | Strong Buy | Maintains | $300 → $325 | +13.91% | May 2, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $284 → $268 | Hold | Maintains | $284 → $268 | -6.07% | Apr 11, 2025 |
| Needham | Needham | Strong Buy Reiterates $320 | Strong Buy | Reiterates | $320 | +12.16% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $500 | Strong Buy | Reiterates | $500 | +75.25% | Apr 2, 2025 |
Financial Forecast
Revenue This Year
2.93B
from 2.25B
Increased by 30.28%
Revenue Next Year
3.82B
from 2.93B
Increased by 30.25%
EPS This Year
-1.67
from -2.18
EPS Next Year
0.81
from -1.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.1B | 5.9B | 6.9B | ||
| Avg | 2.9B | 3.8B | 4.8B | ||
| Low | 2.4B | 2.8B | 3.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 39.8% | 101.5% | 82.0% | ||
| Avg | 30.3% | 30.2% | 26.4% | ||
| Low | 7.9% | -5.9% | -7.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.45 | 4.84 | 9.32 | ||
| Avg | -1.67 | 0.81 | 5.71 | ||
| Low | -3.59 | -3.11 | 1.48 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,047.4% | ||
| Avg | - | - | 603.2% | ||
| Low | - | - | 82.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.